{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:53:11Z","timestamp":1777420391334,"version":"3.51.4"},"reference-count":51,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2017,9,15]],"date-time":"2017-09-15T00:00:00Z","timestamp":1505433600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2018,2]]},"abstract":"<jats:p>Objective: To review the efficacy and safety of defibrotide as well as its pharmacology, mechanism of action, pharmacokinetics (PK), drug-drug interactions, dosing, cost considerations, and place in therapy. Data Sources: A PubMed search was performed through August 2017 using the terms defibrotide, oligonucleotide, hepatic veno-occlusive disease (VOD), sinusoidal obstruction syndrome (SOS), and hematopoietic cell transplantation (HCT). Other data sources were from references of identified studies, review articles, and conference abstracts plus manufacturer product labeling and website, the Food and Drug Administration website, and clinicaltrials.gov. Study Selection and Data Extraction: English-language trials that examined defibrotide\u2019s pharmacodynamics, mechanism, PK, efficacy, safety, dosing, and cost-effectiveness were included. Data Synthesis: Trials have confirmed the safety and efficacy of defibrotide for treatment of VOD\/SOS in adult and pediatric HCT patients, with complete response rates and day +100 overall survival rates ranging from 25.5% to 76% and 35% to 64%, respectively. The British Committee for Standards in Haematology\/British Society for Blood and Marrow Transplantation Guidelines recommend defibrotide prophylaxis in pediatric and adult HCT patients with risk factors for VOD\/SOS; however, its prophylactic use in the United States is controversial. Although there are efficacy data to support this strategy, cost-effectiveness data have not shown it to be cost-effective. Defibrotide has manageable toxicities, with low rates of grade 3 to 4 adverse effects. Conclusions: Defibrotide is the first medication approved in the United States for the treatment of adults and children with hepatic VOD\/SOS, with renal or pulmonary dysfunction following HCT. Data evaluating defibrotide for VOD\/SOS prevention are conflicting and have not shown cost-effectiveness.<\/jats:p>","DOI":"10.1177\/1060028017732586","type":"journal-article","created":{"date-parts":[[2017,9,15]],"date-time":"2017-09-15T09:40:08Z","timestamp":1505468408000},"page":"166-174","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":15,"title":["Defibrotide: An Oligonucleotide for Sinusoidal Obstruction Syndrome"],"prefix":"10.1177","volume":"52","author":[{"given":"May T.","family":"Aziz","sequence":"first","affiliation":[{"name":"Virginia Commonwealth University Health System\/Medical College of Virginia Hospitals, Richmond, VA, USA"},{"name":"Virginia Commonwealth University School of Pharmacy, Richmond, VA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Payal P.","family":"Kakadiya","sequence":"additional","affiliation":[{"name":"Virginia Commonwealth University Health System\/Medical College of Virginia Hospitals, Richmond, VA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha M.","family":"Kush","sequence":"additional","affiliation":[{"name":"Virginia Commonwealth University Health System\/Medical College of Virginia Hospitals, Richmond, VA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kylie","family":"Weigel","sequence":"additional","affiliation":[{"name":"Virginia Commonwealth University Health System\/Medical College of Virginia Hospitals, Richmond, VA, USA"},{"name":"Massachusetts General Hospital, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise K.","family":"Lowe","sequence":"additional","affiliation":[{"name":"Virginia Commonwealth University Health System\/Medical College of Virginia Hospitals, Richmond, VA, USA"},{"name":"Virginia Commonwealth University School of Pharmacy, Richmond, VA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2017,9,15]]},"reference":[{"key":"bibr1-1060028017732586","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2009.08.024"},{"key":"bibr2-1060028017732586","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704069"},{"key":"bibr3-1060028017732586","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-198712000-00011"},{"key":"bibr4-1060028017732586","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-118-4-199302150-00003"},{"key":"bibr5-1060028017732586","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2016.130"},{"key":"bibr6-1060028017732586","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2007.08.002"},{"key":"bibr7-1060028017732586","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-01-0255"},{"key":"bibr8-1060028017732586","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30103-5"},{"key":"bibr9-1060028017732586","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-169342"},{"key":"bibr10-1060028017732586","first-page":"549","volume":"127","author":"Shulman HM","year":"1987","journal-title":"Am J Pathol"},{"key":"bibr11-1060028017732586","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V85.11.3005.bloodjournal85113005"},{"key":"bibr12-1060028017732586","doi-asserted-by":"publisher","DOI":"10.3109\/10428199809059219"},{"key":"bibr13-1060028017732586","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702069"},{"key":"bibr14-1060028017732586","unstructured":"Defitelio\n                      \u00ae\n                      (defibrotide) [prescribing information]. Palto Alto, CA: Jazz Pharmaceuticals, Inc; 2016."},{"key":"bibr15-1060028017732586","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12558"},{"key":"bibr16-1060028017732586","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.262"},{"key":"bibr17-1060028017732586","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2010.02.009"},{"key":"bibr18-1060028017732586","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(93)90864-E"},{"key":"bibr19-1060028017732586","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1996.tb15427.x"},{"key":"bibr20-1060028017732586","doi-asserted-by":"publisher","DOI":"10.1007\/BF00609244"},{"key":"bibr21-1060028017732586","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403004"},{"key":"bibr22-1060028017732586","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61938-7"},{"key":"bibr23-1060028017732586","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7158.1995.tb05789.x"},{"key":"bibr24-1060028017732586","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V100.1.334"},{"key":"bibr25-1060028017732586","unstructured":"Center for Drug Evaluation and Research. Clinical pharmacology and biopharmaceutics review(s). Application number: 208114Orig1s000. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/208114Orig1s000ClinPharmR.pdf. Accessed June 5, 2017."},{"key":"bibr26-1060028017732586","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S112181"},{"key":"bibr27-1060028017732586","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701650"},{"key":"bibr28-1060028017732586","first-page":"737","volume":"92","author":"Richardson PG","year":"1998","journal-title":"Blood"},{"key":"bibr29-1060028017732586","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.02475.x"},{"key":"bibr30-1060028017732586","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.9.1729"},{"key":"bibr31-1060028017732586","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-10-676924"},{"key":"bibr32-1060028017732586","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2016.07.001"},{"key":"bibr33-1060028017732586","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.03.008"},{"key":"bibr34-1060028017732586","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2004.01.002"},{"key":"bibr35-1060028017732586","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705696"},{"key":"bibr36-1060028017732586","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2006.01086.x"},{"key":"bibr37-1060028017732586","doi-asserted-by":"publisher","DOI":"10.1177\/030006058901700105"},{"key":"bibr38-1060028017732586","first-page":"347","volume":"20","author":"Porta R.","year":"1990","journal-title":"Haemostasis"},{"key":"bibr39-1060028017732586","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V122.21.4804.4804"},{"key":"bibr40-1060028017732586","unstructured":"US Food and Drug Administration, Center for Drug Evaluation and Research. Defitelio NDA 208114 clinical pharmacology and biopharmaceutics review, July 31, 2015. http:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=208114. Accessed December 26, 2016."},{"key":"bibr41-1060028017732586","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.08.013"},{"key":"bibr42-1060028017732586","doi-asserted-by":"publisher","DOI":"10.1016\/j.hemonc.2017.02.005"},{"key":"bibr43-1060028017732586","unstructured":"Redbook [online database]. Defibrotide. http:\/\/redbook.com\/redbook\/online. Accessed December 26, 2016."},{"key":"bibr44-1060028017732586","unstructured":"Jazz Pharmaceuticals, Inc. JumpStart: Defitelio (defibrotide) patient assistance site. https:\/\/www.jazzpharma.com\/responsibility\/patient-assistance\/. Accessed December 26, 2016."},{"key":"bibr45-1060028017732586","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2016.1275652"},{"key":"bibr46-1060028017732586","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.03.022"},{"key":"bibr47-1060028017732586","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-04-1216"},{"key":"bibr48-1060028017732586","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704329"},{"key":"bibr49-1060028017732586","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2016.04.011"},{"key":"bibr50-1060028017732586","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14727"},{"key":"bibr51-1060028017732586","unstructured":"Jazz Pharmaceuticals. Study comparing efficacy and safety of defibrotide vs best supportive care in the prevention of hepatic veno-occlusive disease in adult and pediatric patients. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02851407?term=defibrotide&draw=1&rank=5. Accessed June 20, 2017."}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028017732586","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1060028017732586","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028017732586","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:14:03Z","timestamp":1777374843000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1060028017732586"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,15]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["10.1177\/1060028017732586"],"URL":"https:\/\/doi.org\/10.1177\/1060028017732586","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,15]]}}}